The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

 The nephrology drugs market has witnessed significant growth in recent years, with a steady rise in market size and a promising outlook for the future. The market, valued at $16.18 billion in 2023, is projected to reach $17.08 billion in 2024, representing a compound annual growth rate (CAGR) of 5.6%. This growth is attributed to several key factors, including the increasing prevalence of chronic kidney diseases (CKD), advancements in drug development, rising awareness and diagnosis rates, government initiatives, and healthcare policies.

Strong Growth Trajectory

The market is expected to continue its strong growth in the coming years, reaching $21.53 billion by 2028, with a CAGR of 6.0%. Factors driving this growth include emerging therapies and drug innovations, precision medicine, increasing healthcare expenditure, telehealth and remote patient monitoring, and global health initiatives.

Key Trends Driving Growth

Several key trends are expected to drive growth in the nephrology drugs market. These include collaborations and partnerships, technological advancements in dialysis, advancements in treatment modalities, growing emphasis on early diagnosis and intervention, and technological integration in nephrology management. These trends are expected to shape the future of the market, offering new opportunities for growth and innovation.

View More On The Nephrology Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

Surging Incidence of Diabetes and Hypertension

The high incidence of diabetes and hypertension is expected to fuel the growth of the nephrology drug market in the coming years. Diabetes and hypertension are known to be leading causes of chronic kidney disease, leading to an increased demand for nephrology medicines. For instance, according to the World Health Organization, more than 2.5 million hypertension patients were registered in approximately 15,000 health institutions by April 2022. Similarly, the Centers for Disease Control reported that an estimated 37.3 million people worldwide have diabetes.

Product Innovation Driving Market Dynamics

Product innovation is a key trend in the nephrology drug market, with major companies introducing new products and drugs to sustain their market position. For example, Zydus Lifesciences launched Oxemia (desidustat) for chronic kidney disease in March 2022, providing a convenient therapeutic option for the treatment of anemia. This trend of innovation is expected to continue, offering new treatment options and enhancing patients’ quality of life.

Request A Sample Of The Global Nephrology Drugs Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=10076&type=smp

Acquisitions and Mergers to Strengthen Market Presence

Acquisitions and mergers are also shaping the nephrology drugs market, with companies seeking to expand their product portfolios and market presence. In December 2021, CSL Behring AG acquired Vifor Pharma AG for $11.7 billion, expanding its product portfolio in nephrology and dialysis.

Market Segmentation and Regional Outlook

The nephrology drugs market is segmented by drugs, route of administration, distribution channel, and end user. By region, North America was the largest market in 2023, with Europe expected to be the second-largest growing region in 2023.